SCHEMBL19709656

SCHEMBL19709656

Cc1ccc(C(=O)O)c(=O)n1Cc1ccc(F)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
APOBEC3A P31941 1/20 0.47
RECQL P46063 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19692196 0.88 LMNA (0.50) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL11607355 0.81 PKM (0.51) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL19692380 0.81 CNR1 (0.51) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL4430834 0.80 NOTUM (0.60) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL5508929 0.80 CNR2 (0.52) ALDH1A1KDM4EGAAL3MBTL1CNR1
SCHEMBL13534157 0.79 L3MBTL1 (0.44) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL11611071 0.77 ERCC5 (0.48) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL2621619 0.74 SMN1; SMN2 (0.53) ALDH1A1MEN1KMT2AKDM4EL3MBTL1
SCHEMBL2621644 0.74 P2RY14 (0.48) ALDH1A1GAAL3MBTL1PTGDR2P2RY14
SCHEMBL5513138 0.74 CNR2 (0.55) ALDH1A1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190160049-A1 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) 2019-05-30 US disclosed
US-20190160049-A1 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) 2019-05-30 US disclosed
WO-2017211946-A1 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) 2017-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190160049-A1 2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA PDK1, PDK2, PDK3 ALDH1A1 486/4885MEN1 1918/4885KMT2A 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.